← Russell 3000 cross-section

JNJ JOHNSON & JOHNSON

Trailing twelve months to 2026-06-28 · as filed 2026-07-23, not restated
Healthcare

Scale

Market cap
$642.1bn
Revenue TTM
$97.9bn
Net income TTM
$21.0bn
Free cash flow
$22.2bn
Composite score
Sector rank
#18

Valuation

P / E
30.5
EV / EBITDA
EV / sales
6.8
FCF yield
3.46%
Earnings yield vs 10-yr
-1.45pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
21.5%
EBITDA margin
ROE
24.8%
ROIC
Revenue growth
8.1%

Insider activity, last 90 days

Net open-market
$-60.96m
Buyers
0
Sellers
5

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

results of operations Results of operations Sales to customers Analysis of consolidated sales For the fiscal six months of 2026, worldwide sales were $49.4 billion, a total increase of 8.2%, including an operational* increase of 6.0% as compared to 2025 fiscal six months sales of $45.6 billion. In the fiscal six months of 2026, acquisitions and divestitures had net positive impact of 0.5%, on worldwide operational sales growth, primarily related to CAPLYTA. In the fiscal six months of 2026, the negative impact of the STELARA sales decline, due to biosimilar competition, on worldwide operational sales was approximately 5.0%. Sales by U.S. …JOHNSON & JOHNSON, 10-Q, period ended 2026-06-28, filed 2026-07-23

Read the full passage →